The Ebola vaccine stimulates a long-term immune response one year after immunization
The prime-boost vaccine against Ebola virus resulted in a one-year antibody response of at most 100% of healthy individuals in clinical trials. The EU’s Innovative Medicines Initiative assisted with the development of the vaccine.
The success of a recent phase I clinical trial, published in The Journal of the American Medical Association, “indicates that the tested prime-boost vaccine induced the required immune response,” according to a press release. The EBOVAC1 project, funded by the Innovative Medicines Initiative, and led by Oxford University, produced the findings described.
A research published in the December 7 issue of The Lancet Infectious Diseases evaluated the safety and immunogenicity of a vaccine given to healthy persons between the ages of 18 and 50 years old. Following up on 64 individuals after 360 days, all of whom received the active vaccination, 64 individuals were found to have an antibody (immunoglobulin G
The vaccine is a viral vector, which is a harmless virus that has been modified to safely drive the expression of the target virus’s key protein. It’s an established technique in the fight against several infections
The EBOVAC1 project, which includes such well-known institutions as Oxford University, the London School of Hygiene and Tropical Medicine, and the National Institute for Health and Medical Research in France, is a collaboration among partners. The project’s goal is to assess the safety and efficacy of a novel prophylactic prime-boost vaccine against
The project partners will concentrate on two of the three planned studies: phase I and IIB. Phase I will involve 300 participants to assess the safety and immunogenicity of the proposed prime-boost regimen in its early stages. Because the epidemic has ended, and because authorities have granted permission to use a modified version of this vaccine under certain conditions or at. The efficacy assessment in the phase 2b/3 study will evaluate safety and immunogenicity, as well as information on immunogenicity in animals and efficacy data. Safety and immunogenicity trials will be set up to specifically examine the health of adults and children.
In order to test the vaccine, the EBOVAC2 team will give it to selected population groups such as children (1-17 years old), elderly (50-65 years old) and HIV-infected individuals for its safety and immunogenicity. Another major aim will be to build African health centers, their staff and infrastructure for the
A vaccine that stimulates a long-lasting immunity response is critical for maintaining persistent protection against disease, both during epidemics and among susceptible persons. People who have died from the virus are also at higher risk of further infection. These include health workers and humanitarian aid workers in high-risk areas, people living in those areas with low-grade endemic illness, and individuals who come into contact with individuals that have recovered from Ebola virus infection. Given the fact that the virus is present in bodily fluids for.
Evaluating Optimal Vaccine Schedules against Ebola’ (EVOLVE) study at the Oxford Vaccine Group, part of the University of Oxford.